Clinical Trial Update: A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating different dosing strategies to increase the dose of NNC0519-0130 in adults with obesity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• NNC0519-0130

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Obesity | Phase 1 | Status: COMPLETED